Dec 23, 2016: Anti-AXL Biologic Increases Tumor Sensitivity to Radiation and Check-Point
Inhibitors 46
Dec 19, 2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical
models of pain caused by anti-cancer drugs 46
Dec 15, 2016: Cellectis Announces Recombinant DNA Advisory Committee's (RAC) Unanimous
Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN 47
Dec 07, 2016: Personalized Cancer Vaccine is Associated With Promising Outcomes for Patients
with Acute Myeloid Leukemia 47
Dec 06, 2016: Oncternal Therapeutics Presented Data on TK216 at American Society of Hematology
Meeting 48
Dec 06, 2016: Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2
Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms
(MPN) at ASH 48
Dec 06, 2016: Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual
Meeting of American Society of Hematology 49
Dec 06, 2016: Immunotherapy shows promise in preventing leukemia relapse 49
Dec 06, 2016: Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016
ASH Annual Meeting 50
Dec 05, 2016: Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of
Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced
Hematologic Malignancies 50
Dec 05, 2016: Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of
Hematology 2016 Annual Meeting 51
Dec 05, 2016: Sunesis Pharmaceuticals Announces Presentation of Updated Results from the
VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with
Relapsed/Refractory AML at the ASH Annual Meeting 53
Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute
Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American
Society of Hematology 54
Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class
Axl Inhibitor BGB324 In AML at ASH 2016 54
Dec 05, 2016: Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical
Presentations at the American Society of Hematology 2016 Annual Meeting 55
Dec 05, 2016: Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data